RF Acquisition Corp II Right
RFAIR
NASDAQ Global Market0.10
USD
- -
- -
CIK
0002012807
ISIN
KYG753891178
Return %
Stock
S&P500
1Y
34.01
26.53
3Y
17.65
76.60
5Y
17.65
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Tse Meng Ng
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- No. 05-07, 111 Somerset Singapore Cayman Islands
- IPO Date
- Aug 20, 2024
- CIK
- 0002012807
- Website
- rfacquisitioncorp.com
- Similar Companies
- Business
- RF Acquisition Corp II operates as a blank check company incorporated in 2024 and headquartered in Singapore. The company specializes in effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations. It primarily targets businesses within the technology sector including artificial intelligence, quantum computing, and biotechnology with a focus on Asia and Southeast Asia. The company does not engage in any significant operational activities or generate revenue itself but seeks growth opportunities through strategic acquisitions. Recently, RF Acquisition Corp II entered into a business combination agreement with Nanyang Biologics Pte. Ltd., valued at approximately $1.5 billion, in a reverse merger transaction anticipated to complete in early 2026. This transaction intends to bring Nanyang Biologics public via Nasdaq under the ticker symbol NYB. The combination aims to leverage Nanyang Biologics’ biotech platform and leadership team while benefiting from RF Acquisition Corp II's SPAC structure and capital. This represents a major strategic expansion, aligning the company from a blank check platform to an operating biotech entity with substantial presence in Asia's biotech sector. RF Acquisition Corp II successfully closed its $100 million initial public offering in May 2024, listing its units on Nasdaq and positioning itself for future business combinations. The company’s governance includes robust compliance frameworks and investor protections typical of SPACs, holding IPO proceeds in trust until deployment in business combinations. The company operates globally with a focus on Asia, providing investors exposure to emerging technologies and biotech trends via its acquisition strategy. Its target customers and markets are primarily private and public companies within high-growth technology sectors and investors seeking exposure to these industries through a public vehicle. In summary, RF Acquisition Corp II is a Singapore-based blank check company founded in 2024, focused on acquiring technology and biotech businesses in Asia, which recently announced a transformative $1.5 billion merger with Nanyang Biologics to transition into a publicly listed biotech entity on Nasdaq. The company combines a strategic merger approach with a focus on emerging tech and biotech markets in Asia.